tim wallis, founder and managing director, ridgeway biologicals ltd

12
Autogenous Vaccines in Principle and Practice An opportunity in Asia? Tim Wallis BSc PhD Ridgeway Biologicals Ltd, Units 1-3 Old Station Business Park, Compton, Berkshire, U.K. www.ridgewaybiologicals.co.uk

Upload: kisaco-research

Post on 14-Feb-2017

61 views

Category:

Business


1 download

TRANSCRIPT

Page 1: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous Vaccines in Principle and PracticeAn opportunity in Asia?

Tim Wallis BSc PhD

Ridgeway Biologicals Ltd, Units 1-3 Old Station Business Park, Compton, Berkshire, U.K.

www.ridgewaybiologicals.co.uk

Page 2: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Why do we need autogenous vaccines?

• Bacteria are continuously evolving– emergence of new variants– resulting in conventional vaccine breakdowns

• Changes in farming practices create newly susceptible populations– emergence of “new pathogens”– new fully licensed products take 5yrs to develop

• Fully licenced vaccines – not always available

• Autogenous vaccines can provide a rapid solution– reduce dependence on antibiotics

Page 3: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous (emergency) vaccines- definitions

• Derived from pathogens isolated from the target farm/production system

• Inactivated vaccines• Used where fully licensed products have proved ineffective or

are unavailable• Have to be manufactured in premises licenced by regulatory

authorities– Using QA assured manufacturing/QC processes

• Used under the supervision of veterinary surgeon

Page 4: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

High specification manufacturing facilityResourced with committed team

Strong Customer focusHighly skilled workforceResponsive vaccine manufacturing processesAdaptable production schedulingRobust Quality Assurance

“near cGMP”Strong R&D ethos

Page 5: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Pathogen submission/strain analysis

Isolation of pathogens pre- and post-saleGood liaison: Veterinary surgeon Expert local diagnostic laboratory

BacteriologyMolecular biologyCell cultureVirology

Vaccine manufacturer

Page 6: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous vaccine products: poultry

• Pasteurella sp• Riemerella anatipestifer• Erysipelothrix rhusiopathiae • Salmonella sp • Mycoplasma gallisepticum• Mycoplasma synoviae• Gallibacterium anatis• Ornithobacter rhinotrachealis• E.coli• Avian Influenza• Newcastle disease

LayersBroiler breedersTurkeysDucksGeeseGame birds

Multivalent vaccines can simplify vaccination programs

Vaccines adjuvated with oil or alhydrogel

Page 7: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous Vaccine products: Pigs

Actinobacillus pleuropnumoniaHaemophilus parasuisSalmonella speciesStreptococcus suisBrachyspira hyodysenteriaeMycoplasma hyosynoviae/hyorhinis/hyopneumoniaePRRSSwine flu

Page 8: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous vaccine products: aquatic species

Vibrio speciesTenacibaculum maritimus Flavobacterium psychrophilumYersinia ruckeriPseudomonas anguillosepticumPhotobacterium damseliaeAeromonas salmonicidaStreptococcus speciesNodavirusViral Haemorrhagic Septicaemia

Atlantic Cod SalmonTroutSea BassTilapiaOlive flounderCleaner fishDisplay fish

Page 9: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Understanding route to Asian market

Better understand: Veterinary medicines regulations State Veterinary health service provisionIdentify lead: Veterinary Diagnostic LaboratoriesUnderstand disease issues of main: Poultry broiler breeders Table egg producers Commercial duck producers Pig integrators Aquaculture sectorsTarget market prioritiesDevelop the supply chain Logistically possible?

Page 10: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous vaccines: Summary (1)

• Fully licenced vaccines are not always available for the diseases of minor species

• Microbial pathogens are continuously evolving leading to the emergence of new strains

• Conventional vaccines are not always able to provide cross-protection against all variants of pathogens

• Autogenous vaccines are derived from farm-specific pathogens and can control new outbreak strains

• High quality products manufactured in regulated premises with defined and controlled processes

Page 11: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Autogenous vaccines: Summary (2)

• Formulated to the specific requirements of each client – planning is required as they are bespoke products

• Rapid, adaptable response to new emerging infections

• Valuable resource for controlling infectious disease– can help reduce dependence on antibiotics

• Not an alternative to good management, good nutrition and other prophylactic measures

Page 12: Tim Wallis, Founder and Managing Director, Ridgeway Biologicals Ltd

Thanks for listening